Cisplatin combo needed to improve treatment response in thoracic sarcomas
In a retrospective cohort analysis, the survival outcomes of 157 patients with unresectable/advanced primary thoracic sarcoma including 50 cases of primary pulmonary sarcomas (PPS) and 107 cases of chest wall sarcomas (CWS) were analyzed to compare the efficacy of epirubicin, cisplatin plus ifosfamide (E/C/I) versus standard chemotherapy.
Amongst those with PPS, excluding 4 that were found to not be true soft tissue sarcomas, the most common histology was undifferentiated sarcomas. Of these patients, 63% of participants were treated with E/C/I and 37% with another regimen. A benefit to progression-free survival (PFS) and overall survival (OS) was demonstrated in the E/C/I treatment group when compared to any other regimen and to non-platinum regimens.
Amongst those with CWS, the most common histology was synovial and undifferentiated sarcomas. Of these patients, 55.1% of participants were treated with E/C/I and 44.9% with another regimen. No benefit to progression-free survival (PFS) and overall survival (OS) was demonstrated in the E/C/I treatment group when compared to any other regimen and to non-platinum regimens.
When E/C/I was compared to other platinum regimens, a benefit in OS and PFS was demonstrated. In both PPS case and CWS cases, a benefit in favor of cisplatin therapies was demonstrated compared to carboplatin in both OS and PFS.
“The regimen proposed here could represent a possible new standard of treatment for PPS as long as it is validated in a prospective study,” the study authors concluded.
Rodriguez-Cid JR, Juarez-Vignon Whaley JJ, Sánchez-Domínguez G, et al. Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. J Cancer Res Clin Oncol. 2022;doi: 10.1007/s00432-022-04454-8. Epub ahead of print. PMID: 36463530.